These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 23030695)

  • 81. Phase II trial of temsirolimus alone and in combination with irinotecan for KRAS mutant metastatic colorectal cancer: outcome and results of KRAS mutational analysis in plasma.
    Spindler KL; Sorensen MM; Pallisgaard N; Andersen RF; Havelund BM; Ploen J; Lassen U; Jakobsen AK
    Acta Oncol; 2013 Jun; 52(5):963-70. PubMed ID: 23514584
    [TBL] [Abstract][Full Text] [Related]  

  • 82. KRAS analysis in colorectal carcinoma: analytical aspects of Pyrosequencing and allele-specific PCR in clinical practice.
    Sundström M; Edlund K; Lindell M; Glimelius B; Birgisson H; Micke P; Botling J
    BMC Cancer; 2010 Dec; 10():660. PubMed ID: 21122130
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Impact of KRAS mutation on outcome of patients with metastatic colorectal cancer.
    Chang YY; Lin JK; Lin TC; Chen WS; Jeng KJ; Yang SH; Wang HS; Lan YT; Lin CC; Liang WY; Chang SC
    Hepatogastroenterology; 2014 Oct; 61(135):1946-53. PubMed ID: 25713893
    [TBL] [Abstract][Full Text] [Related]  

  • 84. [Detection of KRAS gene mutation and its clinical significance in colorectal adenocarcinoma].
    Xu C; Liu YL; Huang J; He DM; Hou YY; Ji Y; Hou J; Lu SH; Xu JF; Hu Q; Shi Y; Zhao LJ; Tan YS
    Zhonghua Bing Li Xue Za Zhi; 2012 Oct; 41(10):667-70. PubMed ID: 23302307
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Companion-diagnostic testing limited to KRAS codons 12 and 13 misses 17% of potentially relevant RAS mutations in colorectal cancer.
    Netzel BC; Grebe SK
    Clin Chim Acta; 2013 Oct; 425():1-2. PubMed ID: 23832066
    [TBL] [Abstract][Full Text] [Related]  

  • 86. KRAS gene mutation in a series of unselected colorectal carcinoma patients with prognostic morphological correlations: a pyrosequencing method improved by nested PCR.
    de Macêdo MP; de Melo FM; Lisboa BC; Andrade LD; de Souza Begnami MD; Junior SA; Ribeiro HS; Soares FA; Carraro DM; da Cunha IW
    Exp Mol Pathol; 2015 Jun; 98(3):563-7. PubMed ID: 25835782
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Impact of second-line and later cetuximab-containing therapy and KRAS genotypes in patients with metastatic colorectal cancer: a multicenter study in Japan.
    Saeki H; Emi Y; Kumashiro R; Otsu H; Kawano H; Ando K; Ida S; Kimura Y; Tokunaga E; Oki E; Morita M; Shimokawa M; Maehara Y
    Surg Today; 2014 Aug; 44(8):1457-64. PubMed ID: 24013837
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Study of KRAS new predictive marker in a clinical laboratory.
    Bando I; Cillero L; Sanz-Ortega J; Llovet P; Pescador P; Ferrer M; de la Hoya M; Sastre J; García ED; Caldés T
    Clin Transl Oncol; 2012 Dec; 14(12):937-42. PubMed ID: 22865324
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17.
    Vickers MM; Karapetis CS; Tu D; O'Callaghan CJ; Price TJ; Tebbutt NC; Van Hazel G; Shapiro JD; Pavlakis N; Gibbs P; Blondal J; Lee U; Meharchand JM; Burkes RL; Rubin SH; Simes J; Zalcberg JR; Moore MJ; Zhu L; Jonker DJ
    Ann Oncol; 2013 Apr; 24(4):953-60. PubMed ID: 23144444
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Association of Primary Tumor Site With Mortality in Patients Receiving Bevacizumab and Cetuximab for Metastatic Colorectal Cancer.
    Aljehani MA; Morgan JW; Guthrie LA; Jabo B; Ramadan M; Bahjri K; Lum SS; Selleck M; Reeves ME; Garberoglio C; Senthil M
    JAMA Surg; 2018 Jan; 153(1):60-67. PubMed ID: 28975237
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Performance evaluation comparison of 3 commercially available PCR-based KRAS mutation testing platforms.
    Adams JA; Post KM; Bilbo SA; Wang X; Sen JD; Cornwell AJ; Malek AJ; Cheng L
    Appl Immunohistochem Mol Morphol; 2014 Mar; 22(3):231-5. PubMed ID: 24614151
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Association Between Specific Mutations in KRAS Codon 12 and Colorectal Liver Metastasis.
    Margonis GA; Kim Y; Spolverato G; Ejaz A; Gupta R; Cosgrove D; Anders R; Karagkounis G; Choti MA; Pawlik TM
    JAMA Surg; 2015 Aug; 150(8):722-9. PubMed ID: 26038887
    [TBL] [Abstract][Full Text] [Related]  

  • 93. [Correlation between KRAS mutations and clinicopathologic features in colorectal carcinomas].
    Gao J; Zhang J; Lu T; Li XY; Jia N; Liang ZY
    Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):595-8. PubMed ID: 23157826
    [TBL] [Abstract][Full Text] [Related]  

  • 94. [Identification of K-RAS mutations in colorectal cancer patients in Israel].
    Segal G; Liebermann N; Klang S; Siegelmann-Daniel N; Beit-Or A; Klien B; Shoushan-Gutman L
    Harefuah; 2011 May; 150(5):447-50, 491. PubMed ID: 21678640
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Health-related quality of life and colorectal cancer-specific symptoms in patients with chemotherapy-refractory metastatic disease treated with panitumumab.
    Odom D; Barber B; Bennett L; Peeters M; Zhao Z; Kaye J; Wolf M; Wiezorek J
    Int J Colorectal Dis; 2011 Feb; 26(2):173-81. PubMed ID: 21190026
    [TBL] [Abstract][Full Text] [Related]  

  • 96. KRAS mutation correlates with accelerated metastatic progression in patients with colorectal liver metastases.
    Nash GM; Gimbel M; Shia J; Nathanson DR; Ndubuisi MI; Zeng ZS; Kemeny N; Paty PB
    Ann Surg Oncol; 2010 Feb; 17(2):572-8. PubMed ID: 19727962
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Mutant allele-specific imbalance modulates prognostic impact of KRAS mutations in colorectal adenocarcinoma and is associated with worse overall survival.
    Hartman DJ; Davison JM; Foxwell TJ; Nikiforova MN; Chiosea SI
    Int J Cancer; 2012 Oct; 131(8):1810-7. PubMed ID: 22290300
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Influence of KRAS mutation status in metachronous and synchronous metastatic colorectal adenocarcinoma.
    Rose JS; Serna DS; Martin LK; Li X; Weatherby LM; Abdel-Misih S; Zhao W; Bekaii-Saab T
    Cancer; 2012 Dec; 118(24):6243-52. PubMed ID: 22674181
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Reliability of KRAS mutation testing in metastatic colorectal cancer patients across five laboratories.
    Feigelson HS; Goddard KA; Johnson MA; Funk KC; Rahm AK; Kauffman TL; Chitale DA; Le Marchand L; Richards CS
    BMC Res Notes; 2012 Apr; 5():196. PubMed ID: 22534075
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Competitive amplification of differentially melting amplicons (CADMA) improves KRAS hotspot mutation testing in colorectal cancer.
    Kristensen LS; Kjeldsen TE; Hager H; Hansen LL
    BMC Cancer; 2012 Nov; 12():548. PubMed ID: 23173730
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.